Clinical investigators from Moffitt and Walter Reed Army Institute present data of first Phase II Neoepitope Antibody Immunotherapy Clinical Trial completed at John’s Hopkins, Duke and Moffitt as a potential new immunotherapy treatment for cancer care, a Cancer MoonShot 2020 milestone.Read More
NantCare, a member of the NantWorks family of companies responsible for operationalizing the Cancer MoonShot 2020 and QUILT programs, today announced its active engagement with community oncology practices by providing a combination of technology, access to clinical trials and administrative support to optimize community oncology practices’ compliance in the Oncology Care Model (OCM).Read More
NantHealth, Inc.(Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, the Chan Soon-Shiong Institute of Molecular Medicine and the collaborators of the Pediatric Cancer Moonshot 2020 today announced that they are embarking on one of the world’s most ambitious pediatric sequencing discovery projects to date. This initiative will focus on the largest killer of pediatric cancer patients today: childhood brain tumors.Read More
Cancer MoonShot 2020, the nation’s most comprehensive cancer collaborative initiative, today announced the formation of the Inflammatory Breast Cancer Working Group. The team consists of physicians, researchers and oncology professors from across the nation who have come together to focus their collective wisdom and expertise to identify and develop the most effective cancer-directed immunotherapy treatments for inflammatory breast cancer (IBC)Read More
Cancer MoonShot 2020 announced the formation of the Melanoma and Sarcoma Working Group to accelerate molecular-informed immunotherapy trials and to focus on identifying the most effective, cancer-directed immunotherapy treatments for patients with melanoma and sarcoma.Read More
Cancer MoonShot 2020 announced the formation of the Head and Neck Working Group which will work to identify and develop the most effective cancer-directed immunotherapy treatments for Head and Neck cancers.Read More
Cancer MoonShot 2020 announced the formation of the Breast Cancer Working Group which will work to identify and develop the most effective cancer-directed immunotherapy treatments for breast cancer.Read More
NantHealth, Inc. (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, announced today the commercial availability of Genomic Proteomic Spectrometry Cancer, or GPS Cancer™.Read More
NantKwest provided an update today on the company’s clinical programs as part of the Cancer MoonShot 2020 initiative in a presentation at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, Nevada.Read More
NantHealth, LLC announced the expanded adoption of GPS Cancer, a unique comprehensive molecular test to help oncology care providers guide treatment strategies for cancer care, by partnering with major self-insurers that have agreed to cover the costs for their employees requiring this test.Read More
NantKwest, Inc (Nasdaq:NK), today announced that Dr. Patrick Soon-Shiong, NantKwest’s Chairman and CEO will be giving the Keynote address and NantKwest will be presenting at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, Nevada on Tuesday, May 10, 2016.Read More
Dr. Patrick Soon-Shiong was honored at the Vatican with the 2016 Pontifical Key Visionary Award which recognizes medical innovators who change the course of history and reduce suffering on a global scale by blending visionary thinking with real action.Read More
NantOmics announces CLIA certification and CAP accreditation, making it the nation's first and only CLIA-certified, CAP-accredited laboratories to perform whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics.Read More
Cancer MoonShot 2020 announced the formation of a Radiation and Immuno-Oncology Working Group which will work to identify the most effective combinations of low dose radiation (LDR) with cancer-directed immunotherapy.Read More
Physician Scientist and inventor of Abraxane to participate with 28 cancer community thought leaders to help inform the scientific direction at the NCI of the National Cancer Moonshot Initiative
CULVER CITY, Calif. – April 7, 2016 – The National Cancer Institute announced the selection of Patrick Soon-Shiong, M.D., FRCs (c), FACS to the Blue Ribbon Panel of scientific experts, cancer leaders and patient advocates that will inform the scientific direction and goals at the National Cancer Moonshot Institute of Vice President Joe Biden’s National Cancer Moonshot Initiative.
Dr. Soon-Shiong will be a member of the panel of experts that will provide recommendations to the National Cancer Advisory Board, which advises the NCI, on how to advance the themes that have been proposed for the initiative. The themes include the development of cancer vaccines, highly sensitive approaches to early detection, advances in immunotherapy and combination therapies, single-cell genomic profiling of cancer cells and cells in the tumor microenvironment, enhanced data sharing, and new approaches to the treatment of pediatric cancers.
The 28-member Blue Ribbon Panel brings together a group of cancer thought leaders to address opportunities in prevention, diagnosis and treatment of cancer. The panel includes extramural investigators, members of the public, cancer advocacy groups, pharmaceutical and biotechnology industries and communities with expertise in clinical trials and health disparities.
“It’s an extremely exciting time in the history of the war against cancer— our program, Cancer MoonShot 2020, and Vice President Biden’s National Cancer Moonshot are important calls to action to urge collaboration in order to make impactful strides, accelerate progress, and win this war,” said Patrick Soon-Shiong, CEO of NantWorks and leader of the Cancer MoonShot 2020, a non-profit cancer collaborative. “It’s an honor to join the Blue Ribbon Panel and have the opportunity to share the steps we have already taken with Cancer MoonShot 2020 to accelerate immunotherapy development and drive comprehensive pan-omic precision cancer care. We are most excited by the strides we have made in engaging both community oncologists and the pediatric community in our efforts to establish a Cancer Moonshot Network to accelerate clinical trials,” he said.Read More